| 12/05 | Insider Sell: Veracyte | MT |
| 11/30 | Transcript : Exact Sciences Corporation Presents at Piper Sandler 34th Annual.. | CI |
| 11/29 | Transcript : Exact Sciences Corporation Presents at 5th Annual Evercore ISI H.. | CI |
| 11/18 | JPMorgan Chase Cuts Price Target on Guardant Health to $85 From $100, Maintains Overwei.. | MT |
| 11/17 | Insider Sell: Guardant Health | MT |
| 11/15 | Transcript : Exact Sciences Corporation Presents at 13th Annual Jefferies Lon.. | CI |
| 11/14 | Piper Sandler Boosts Price Target for Exact Sciences to $50 From $40, Maintains Neutral.. | MT |
| 11/08 | Transcript : Exact Sciences Corporation Presents at Credit Suisse 31st Annual.. | CI |
| 11/08 | Transcript : Veracyte, Inc. Presents at Credit Suisse 31st Annual Healthcare .. | CI |
| 11/07 | Stephens Adjusts Price Target on Guardant Health to $90 From $99, Maintains Overweight .. | MT |
| 11/07 | Raymond James Adjusts Price Target on Exact Sciences to $60 From $70, Maintains Outperf.. | MT |
| 11/07 | BTIG Adjusts Price Target on Exact Sciences to $65 From $70, Maintains Buy Rating | MT |
| 11/04 | Sector Update: Health Care Stocks Higher Amid Late Markets Advance | MT |
| 11/04 | Sector Update: Health Care Stocks Sliding as Broader Markets Flit Between .. | MT |
| 11/04 | Raymond James Adjusts Price Target on Veracyte to $27 From $31, Maintains Outperform Ra.. | MT |
| 11/04 | Credit Suisse Lowers Guardant Health's Price Target to $70 From $80, Keeps Outperform R.. | MT |
| 11/03 | Exact Sciences Q3 Loss Narrows as Sales Jump, Ups Revenue Guidance; Shares Jump After-H.. | MT |
| 11/03 | Guardant Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months En.. | CI |
| 11/03 | Exact Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Mont.. | CI |
| 11/03 | Transcript : Exact Sciences Corporation, Q3 2022 Earnings Call, Nov 03, 2022 | CI |
| 11/03 | Transcript : Guardant Health, Inc., Q3 2022 Earnings Call, Nov 03, 2022 | CI |
| 11/03 | Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Loss $-0.84 | MT |
| 11/03 | Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $523.1M, vs. Street.. | MT |
| 11/03 | Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Loss $-0.84, vs. Street Est.. | MT |
| 11/03 | Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Loss $-1.18, vs. Street Est of $-1.08 | MT |
| 11/03 | Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Revenue $117.4M, vs. Street Est of $117.9M | MT |
| 11/03 | Exact Sciences Corporation Reports Impairment Charges for the Third Quarter Ended Septe.. | CI |
| 11/03 | Exact Sciences Corporation Revises Revenue Guidance for the Full Year of 2022 | CI |
| 11/03 | Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022 | CI |
| 11/03 | SVB Securities Adjusts Veracyte's Price Target to $35 From $30, Keeps Outperform Rating | MT |
| 11/03 | Needham Adjusts Price Target on Veracyte to $33 From $31, Maintains Buy Rating | MT |
| 11/03 | Earnings Reaction History: EXACT SCIENCES, 40.0% Follow-Throug.. | MT |
| 11/02 | Transcript : Veracyte, Inc., Q3 2022 Earnings Call, Nov 02, 2022 | CI |
| 11/02 | Earnings Flash (VCYT) VERACYTE Posts Q3 Revenue $75.6M | MT |
| 11/02 | Earnings Flash (VCYT) VERACYTE Reports Q3 Loss $-0.12 | MT |
| 11/02 | Veracyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep.. | CI |
| 11/02 | Veracyte, Inc. Raises Revenue Guidance for the Year 2022 | CI |
| 11/01 | Piper Sandler Downgrades Guardant Health to Neutral From Overweight, Adjusts Price Targ.. | MT |
| 10/27 | Beijing Strong Biotechnologies, Inc. Reports Earnings Results for the Nine Months Ended.. | CI |
| 10/25 | Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can H.. | CI |
| 10/24 | Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior | CI |
| 10/19 | Exact Sciences Down Following Craig-Hallum Downgrade | MT |
| 10/19 | Craig-Hallum Initiates Guardant Health at Buy With $88 Price Target | MT |
| 10/19 | Craig-Hallum Downgrades Exact Sciences to Hold From Buy, Lowers Price Target to $35 Fro.. | MT |
| 10/18 | New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Valu.. | CI |
| 10/11 | Ark's Cathie Wood suggests Fed closer to 'pivot' as volatility rises | RE |
| 10/10 | 'Alarm Bells' Ring as China Shuffles Economic Leaders at Critical Time | MT |
| 10/09 | Tranche Update on Beijing Strong Biotechnologies, Inc.'s Equity Buyback Plan announced .. | CI |
| 10/06 | Stephens Starts Guardant Health at Overweight With $99 Price Target | MT |
| 09/22 | Veracyte's Decipher Prostate Genomic Classifier May Help Identify Aggressiveness of Pro.. | MT |
| 09/22 | Veracyte, Inc. Publishes New Data in JNCI Demonstrate its Decipher Prostate Genomic Cla.. | CI |
| 09/13 | Transcript : Exact Sciences Corporation Presents at Baird 2022 Global Healthc.. | CI |
| 09/13 | Transcript : Veracyte, Inc. Presents at Morgan Stanley 20th Annual Global Hea.. | CI |
| 09/13 | Veracyte, Inc. Names John Leite as Senior Vice President and General Manager of Pulmono.. | CI |
| 09/12 | Transcript : Guardant Health, Inc. Presents at Morgan Stanley 20th Annual Glo.. | CI |
| 09/11 | Veracyte, Inc. Announces That New Data from a Phase 3 Trial of the Multi-Center, Multi-.. | CI |
| 09/10 | Exact Sciences Corp. Demonstrates Power of Multi-Cancer Early Detection Approach with D.. | CI |
| 09/09 | Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Hel.. | CI |
| 09/07 | Veracyte to Present Data Supporting Its Genomic Diagnostic Tool at Industry Conference | MT |
| 09/06 | Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Po.. | CI |
| 09/01 | Revolution Medicines Appoints Jack Anders CFO, Daniel Simon Chief Business Officer | MT |
| 08/31 | Guardant Health, Merck KGaA Expand Collaboration to Develop Precision Cancer Therapies | MT |
| 08/31 | Guardant Health, Inc Expands Strategic Collaboration With Merck KGaA, Darmstadt, German.. | CI |
| 08/29 | Veracyte Says Study Indicates Microenvironments May Affect Large B-Cell Lymphoma Patien.. | MT |
| 08/29 | Veracyte, Inc. Announces New Data in Nature Medicine Suggest Pre-Treatment Tumor Microe.. | CI |
| 08/29 | Beijing Strong Biotechnologies, Inc. signed an Equity Transfer Agreement to acquire an .. | CI |
| 08/26 | Beijing Strong Biotechnologies, Inc. Reports Earnings Results for the Half Year Ended J.. | CI |
| 08/25 | Credit Suisse Initiates Exact Sciences at Outperform with $55 Price Target | MT |
| 08/25 | Credit Suisse Starts Guardant Health at Outperform with $80 Price Target | MT |
| 08/19 | Insider Sell: Guardant Health | MT |
| 08/18 | Piper Sandler Cuts Price Target on Exact Sciences to $40 From $50, Reiterates Neutral R.. | MT |
| 08/15 | Insider Sell: Guardant Health | MT |
| 08/15 | Guardant Health Expands Detection Test to Include Breast, Lung Cancers; Shares Gain | MT |
| 08/12 | Guardant Health Says FDA Approved Liquid Biopsy Test as Companion Diagnostic for Lung C.. | MT |
| 08/12 | Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnosti.. | CI |
| 08/11 | Veracyte, Inc. Appoints Eliav Barr to Its Board of Directors | CI |
| 08/10 | Transcript : Guardant Health, Inc. Presents at UBS Genomics 2.0 and Medtech I.. | CI |
| 08/10 | Transcript : Exact Sciences Corporation Presents at UBS Genomics 2.0 and Medt.. | CI |
| 08/08 | Morgan Stanley Adjusts Guardant Health's Price Target to $80 From $85, Keeps Overweight.. | MT |
| 08/08 | Goldman Sachs Cuts Price Target on Guardant Health to $80 From $90, Maintains Buy Ratin.. | MT |
| 08/05 | Guardant Health Q2 Non-GAAP Loss Widens; Maintains 2022 Revenue Outlook | MT |
| 08/04 | Earnings Flash (GH) GUARDANT HEALTH Posts Q2 Loss $-1.00 | MT |
| 08/04 | Earnings Flash (GH) GUARDANT HEALTH Posts Q2 Revenue $109.1M | MT |
| 08/04 | Transcript : Guardant Health, Inc., Q2 2022 Earnings Call, Aug 04, 2022 | CI |
| 08/04 | Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022 | CI |
| 08/04 | Guardant Health, Inc. Reports Earnings Results for the Second Quarter and Six Months En.. | CI |
| 08/04 | Raymond James Adjusts Veracyte's Price Target to $31 from $30 Keeps Outperform Rating | MT |
| 08/04 | Goldman Sachs Cuts Price Target on Veracyte to $32 From $35, Noting Decline in Peer Mul.. | MT |
| 08/04 | Analyst recommendations: Illinois Tool Works, Eaton, Marathon Pe.. | |
| 08/03 | Craig Hallum Lowers Exact Sciences Price Target to $60 From $81, Maintains Buy Rating | MT |
| 08/03 | BTIG Adjusts Price Target on Exact Sciences to $70 From $100, Reiterates Buy Rating | MT |
| 08/03 | Cowen Adjusts Price Target on Exact Sciences to $67 From $83, Keeps Outperform Rating | MT |
| 08/03 | Baird Adjusts Price Target on Exact Sciences to $75 From $90, Keeps Outperform Rating | MT |
| 08/03 | Raymond James Adjusts Price Target on Exact Sciences to $70 From $80, Keeps Outperform .. | MT |
| 08/03 | Citigroup Adjusts Price Target on Exact Sciences to $50 From $65, Maintains Neutral Rat.. | MT |
| 08/03 | Needham Adjusts Veracyte's Price Target to $31 From $26, Citing 'Peer Multiple Expansio.. | MT |
| 08/03 | MDxHealth Agrees to Buy Exact Sciences' Prostate Cancer Unit for Up to $100 Million | MT |
| 08/03 | Belgium's MDxHealth To Buy Exact Sciences' Prostrate Cancer Test For $100 Million | MT |
| 08/02 | Exact Sciences Corporation Reports Earnings Results for the Second Quarter and Six Mont.. | CI |
| 08/02 | Transcript : Exact Sciences Corporation, Q2 2022 Earnings Call, Aug 02, 2022 | CI |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
